The Pharma Data

NOVEMBER 11, 2020

TOKYO & AUSTIN, Texas–( BUSINESS WIRE )– Taiho Pharmaceutical Co., Lung Tx”) announced today an exclusive license agreement of LTI-01 , a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions , for the territory of Japan. “LTI-01

Licensing 40

Licensing Licensing Treatment Pharma Companies 40

PPD

MAY 7, 2024

Challenges and opportunities of the new EU HTA regulation The implementation of centralized HTA presents both opportunities and challenges for pharmaceutical companies. Particularly for small and mid-size pharmaceutical companies, meeting these timelines could be a significant hurdle.

Regulations 52

Regulations Pharmaceutical Companies International Pharmaceuticals 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. Neil is a scientific business leader with thirty years’ experience of the pharmaceutical, biotechnology and life sciences investment industries.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. This highlighted the importance of defining patent scope and licensing terms in such collaborations.

Drug Development 81

Drug Development Clinical Trials Drugs Therapies 81

The Pharma Data

DECEMBER 16, 2020

–( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc. NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Learn more about Otsuka Pharmaceutical Company on its global website at [link].

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

Broad Institute

MAY 14, 2024

Making medicine The T7 technology has also had immediate impacts in industry, with more than 900 biotech and pharmaceutical companies licensing it to produce therapeutics and vaccines. There are more than 100 different versions of the T7 technology available commercially and 12 patents in Studier’s name related to the system.

RNA 84

RNA Production Molecular Biology Laboratories 84

Crown Bioscience

MAY 4, 2021

used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children. Pediatric cancer has been a low priority for pharmaceutical companies due to a combination of factors, including scientific hurdles, additional regulatory burdens, and financial disincentives.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Drug Target Review

SEPTEMBER 7, 2023

A patent lawyer by training, Keir represented companies of various sizes in all stages of transactions, including licensing and M&A. For nearly a decade before this role, he held various commercial roles with OraPharma, a specialty pharmaceutical company that was purchased by Johnson & Johnson.

Treatment 98

Treatment Licensing Licensing Disease 98

The Pharma Data

OCTOBER 9, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past.

FDA Approval 52

FDA Approval Treatment FDA Pharmaceutical Companies 52

The Pharma Data

NOVEMBER 23, 2020

At Ultimovacs, he will lead all business and corporate development efforts and continue to maintain and foster connections with leading biotechnology and pharmaceutical companies. “In Mr. Berkien is currently a board member of the Nordic Pharma Licensing Group.

Clinical Trials 52

Clinical Trials Small Molecule Pharmaceutical Companies Licensing 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. BA HCP ISI 09JUL2020. It is approved in the U.S.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

JANUARY 17, 2021

. “Rolontis,” a treatment for neutropenia that had its technology licensed out to Spectrum Pharmaceuticals, Inc. and “Oraxol,” which was licensed out to Athenex, Inc. “R&D capabilities of Hanmi Pharmaceutical Co., Hanmi Pharmaceutical Co.,

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

NOVEMBER 8, 2020

Sedor is actively engaged in discussions to license the rights to Sesquient for North America, Europe, and other territories except for the Peoples Republic of China, where it has already been successfully licensed. Sedor Pharmaceuticals, LLC identifies, acquires and develops acute care pharmaceutical assets for commercial licensing.

FDA Approval 52

FDA Approval FDA Long-Term Care Facilities Treatment 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced the appointment of Thomas H. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct.

Licensing 40

Licensing Licensing Pharmaceutical Companies Clinical Trials 40

The Pharma Data

DECEMBER 9, 2020

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda. This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda.

Licensing 52

Licensing Licensing Pharmaceutical Companies Engineering 52

The Pharma Data

SEPTEMBER 6, 2021

Takeda today announced that the Government of Japan’s Ministry of Health, Labour and Welfare (MHLW) will purchase 150 million doses of Novavax’ vaccine candidate (TAK-019 in Japan) manufactured in Japan by Takeda subject to licensing and approval. The details of the terms and conditions of the agreement are confidential.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 27, 2022

Janssen) entered into an exclusive worldwide license and collaboration agreement with Legend Biotech USA, Inc. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. In December 2017, Janssen Biotech, Inc.

Therapies 52

Therapies Treatment Pharmaceutical Companies Nurses 52

Molecule Blog

JANUARY 9, 2023

IP-NFTs upgrade our legacy intellectual system by unifying IP (patents, legal), underlying data (through decentralized storage and access control), and economics (royalties, license fees, sales) into one programmable, transactable, digital unit. ‍ Licensing fees and revenue generated flow back to the smart contract (eg.

Research 52

Research Licensing Licensing Science 52

The Pharma Data

DECEMBER 8, 2020

The company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the company’s own clinical development pipeline or for additional licensing and partnering.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

JANUARY 3, 2021

03, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Ocumension Therapeutics, a China-based ophthalmic pharmaceutical company traded on the Stock Exchange of Hong Kong (1477.HK),

Pharmaceuticals 52

Pharmaceuticals Pharmaceutical Companies Licensing Licensing 52

The Pharma Data

FEBRUARY 22, 2021

Under the terms of the settlement agreements, AbbVie and Medytox will release all claims against Evolus related to the alleged misappropriation of Medytox’s trade secrets and grant a license to Evolus to continue to commercialize Jeuveau® in the United States and Nuceiva in all other territories in which Evolus has licensing rights.

Licensing 40

Licensing Licensing Pharmaceutical Companies Production 40

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland China and Taiwan. SHANGHAI , Jan. About Asieris.

Licensing 40

Licensing Licensing Clinical Development Pharmaceutical Companies 40

DrugBaron

NOVEMBER 9, 2020

Indeed, China has already licensed a vaccine, albeit without the data that would typically be required to support such an approval. The global scientific community and pharmaceutical industry is delivering technically challenging innovation at a pace that arguably has never been witnessed before.

Vaccine 100

Vaccine Pharmaceutical Companies Government Pharmaceuticals 100

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

The Pharma Data

NOVEMBER 25, 2020

The Company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Clinical Trials 52

Clinical Trials Licensing Licensing International 52

The Pharma Data

MARCH 16, 2021

In partnering with the Lieber Institute, Boehringer Ingelheim has in-licensed preclinical pipeline candidates, representing a first-in-class approach for targets in neuropsychiatric disorders. The potential of centrally acting COMT inhibitors has not yet been evaluated in the clinic due to the unavailability of such compounds.

Licensing 52

Licensing Licensing Research Laboratories Treatment 52

The Pharma Data

APRIL 22, 2023

Pharmaceutical companies have an ethical responsibility to make their new treatments for diabetes and obesity available for anyone in need, in any country.” The medication is not licensed for obesity alone. Millions of lives have been saved by treating infectious diseases at low cost in poor countries. to $1,100.70.

Medical Schools 40

Medical Schools Licensing Licensing Treatment 40

DrugBank

MARCH 22, 2024

Due to open source data’s accessibility, it is an appealing resource for drug research as it often enables cost-effective sources for emerging pharmaceutical companies and academic research projects.  Paid Knowledge Bases Paying for access or licensing a knowledge base can be a difficult decision to make.

Licensing 74

Licensing Licensing Research Production 74

The Pharma Data

JANUARY 4, 2021

5, 2021 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it is to regain the worldwide rights to its muscarinic agonist programs. The program was licensed to Allergan in April 2016 , and Allergan was acquired by AbbVie in May 2020. ” About the License Agreement.

Licensing 40

Licensing Licensing Clinical Trials Disease 40

The Pharma Data

AUGUST 13, 2020

The vaccines are being developed by the Belgian pharmaceutical company Janssen and the US biotech company Novavax. There are no licensed vaccines for any human coronavirus.” Image copyright. The UK government has signed deals for a further 90 million doses of coronavirus vaccine.

Vaccine 52

Vaccine Virus Government Clinical Trials 52

The Pharma Data

JANUARY 19, 2021

The Company’s validated, proprietary F.I.R.S.T technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company’s own clinical development pipeline or for additional licensing and partnering.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

JANUARY 12, 2021

LONDON, UK / ACCESSWIRE / January 13, 2021 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that it has successfully completed the development of its CDX antibody with a leading global pharmaceutical company (“GlobalCo”).

Pharmaceuticals 40

Pharmaceuticals Licensing Licensing Clinical Trials 40

The Pharma Data

JANUARY 15, 2021

January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. and Genmab A/S entered into a worldwide agreement, which granted Janssen an exclusive license to develop, manufacture and commercialize daratumumab. About Darzalex Faspro® In August 2012, Janssen Biotech, Inc.

FDA Approval 52

FDA Approval Treatment FDA Pharmaceutical Companies 52

The Pharma Data

JANUARY 17, 2021

The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. SHANGHAI , Jan.

Clinical Trials 52

Clinical Trials Clinical Development Pharmacokinetics Pharmaceutical Companies 52

The Pharma Data

JANUARY 26, 2021

Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. BioArctic’s Class B share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B).

Disease 40

Disease Pharmaceutical Companies Treatment Licensing 40

The Pharma Data

NOVEMBER 10, 2020

AlzeCure ® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain – indications for which currently available treatment is extremely limited.

Pharmaceutical Companies 40

Pharmaceutical Companies Disease Treatment Pharmaceuticals 40